CPIX - Cumberland Pharmaceuticals Inc Stock Price, Fair Value and News

1.51USD+0.01 (+0.67%)Delayed

Market Summary

USD1.51+0.01

Delayed

0.67%

CPIX Stock Price

View Fullscreen

CPIX RSI Chart

CPIX Valuation

Market Cap

21.4M

Price/Earnings (Trailing)

-2.55

Price/Sales (Trailing)

0.55

EV/EBITDA

-0.98

Price/Free Cashflow

4.15

CPIX Price/Sales (Trailing)

CPIX Profitability

EBT Margin

-21.52%

Return on Equity

-30.96%

Return on Assets

-10.33%

Free Cashflow Yield

24.08%

CPIX Fundamentals

CPIX Revenue

Revenue (TTM)

38.8M

Rev. Growth (Yr)

-7.88%

Rev. Growth (Qtr)

-9.15%

CPIX Earnings

Earnings (TTM)

-8.4M

Earnings Growth (Yr)

-1.1K%

Earnings Growth (Qtr)

69.08%

Breaking Down CPIX Revenue

Last 7 days

-1.9%

Last 30 days

-3.8%

Last 90 days

-28.1%

Trailing 12 Months

-14.2%

How does CPIX drawdown profile look like?

CPIX Financial Health

Current Ratio

1.37

CPIX Investor Care

Buy Backs (1Y)

1.78%

Diluted EPS (TTM)

-0.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	38.8M	0	0	0
2023	40.1M	40.7M	39.3M	39.6M
2022	36.6M	37.9M	41.2M	42.0M
2021	39.6M	39.1M	37.9M	36.0M
2020	34.0M	34.2M	36.5M	37.4M
2019	32.2M	34.5M	35.6M	34.4M
2018	37.4M	35.8M	30.5M	29.3M
2017	34.9M	36.2M	38.6M	41.2M
2016	32.6M	31.1M	32.0M	33.0M
2015	37.5M	36.7M	34.8M	33.5M
2014	29.9M	32.5M	35.7M	36.9M
2013	48.9M	43.6M	37.6M	32.0M
2012	50.7M	48.7M	48.2M	48.9M
2011	46.4M	50.1M	50.9M	51.1M
2010	0	44.3M	45.1M	45.9M
2009	0	0	0	43.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cumberland Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	galante joseph c	acquired	1,710	1.71	1,000	-
Mar 25, 2024	young caroline	acquired	1,710	1.71	1,000	-
Mar 25, 2024	krogulski kenneth	acquired	8,550	1.71	5,000	-
Mar 25, 2024	jones james	acquired	1,710	1.71	1,000	-
Mar 25, 2024	brown martin s jr	acquired	1,710	1.71	1,000	-
Mar 23, 2024	herman james l	sold (taxes)	-2,146	1.81	-1,186	vp and chief compliance office
Mar 23, 2024	kazimi a j	sold (taxes)	-46,535	1.81	-25,710	chairman and ceo
Mar 23, 2024	bitterman chris t.	sold (taxes)	-1,073	1.81	-593	vice pres sales & marketing
Mar 23, 2024	hamm john m.	sold (taxes)	-805	1.81	-445	vp chief financial officer
Mar 23, 2024	anthony todd m.	sold (taxes)	-1,476	1.81	-816	vice pres organizational dev

Which funds bought or sold CPIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	reduced	-15.31	-12,619	56,616	-%
May 15, 2024	CITADEL ADVISORS LLC	added	2.46	-66.00	6,085	-%
May 15, 2024	Royal Bank of Canada	reduced	-65.94	-	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-17,200	481,580	0.01%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-1.82	-4,698	54,482	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-1.71	-3,286	38,640	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	2.11	-430	9,655	-%
May 15, 2024	Cresset Asset Management, LLC	unchanged	-	-1,343	20,202	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-9.00	-	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-1,260	18,940	-%

Are Funds Buying or Selling CPIX?

Are funds buying CPIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CPIX

No. of Funds

Unveiling Cumberland Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	cumberland pharmaceuticals inc	40.14%	5,721,267	SC 13G
Feb 10, 2023	kazimi a j	39.41%	5,753,358	SC 13G
Feb 14, 2022	kazimi a j	38.33%	5,770,563	SC 13G
Feb 08, 2022	dimensional fund advisors lp	4.4%	652,561	SC 13G/A
Jul 09, 2021	ariel investments, llc	0.1%	12,033	SC 13G/A
Feb 12, 2021	ariel investments, llc	5.5%	821,096	SC 13G/A
Feb 12, 2021	stonepine capital management, llc	1.3%	188,703	SC 13G/A
Feb 12, 2021	cumberland pharmaceuticals inc	37.65%	5,793,069	SC 13G
Feb 12, 2021	dimensional fund advisors lp	5.2%	781,891	SC 13G/A
Feb 14, 2020	ariel investments, llc	6.7%	1,010,220	SC 13G/A

Recent SEC filings of Cumberland Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading

Peers (Alternatives to Cumberland Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Cumberland Pharmaceuticals Inc News

Latest updates

Cumberland Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-9.1%	8,497,701	9,353,066	10,085,926	10,888,877	9,224,638	9,123,680	11,413,072	10,299,152	11,175,045	8,319,861	8,072,540	9,055,483	10,537,159	10,261,534	9,250,689	9,598,177	8,330,734	9,305,553	6,935,439	9,417,443	8,729,860
Costs and Expenses	-33.3%	10,366,951	15,532,305	11,952,529	10,866,018	10,756,316	11,401,484	11,701,660	12,145,690	12,467,044	12,673,857	9,635,935	10,491,212	10,861,459	12,007,480	10,459,375	11,179,139	10,176,735	12,699,943	10,131,875	10,790,867	10,053,792
S&GA Expenses	-12.7%	4,154,588	4,759,230	4,743,142	4,672,075	4,277,318	3,379,434	4,110,397	4,556,685	4,614,429	3,305,979	3,800,288	4,121,817	3,787,340	3,604,541	3,587,842	3,865,406	3,707,676	4,045,962	3,812,467	3,982,379	3,436,932
R&D Expenses	-8.4%	1,158,253	1,264,753	1,924,768	1,145,038	1,499,670	1,405,841	1,714,254	1,823,693	1,745,136	1,612,827	1,453,873	1,360,398	1,257,367	1,399,433	1,230,335	1,421,502	1,722,555	2,079,782	1,672,843	1,716,169	1,399,687
EBITDA Margin	-337.3%	-0.08	-0.02	0.06	0.08	0.04	0.01	-0.03	-0.08	-0.04	-0.02	0.05	0.06	-	-	-	-	-	-	-	-	-
Interest Expenses	-33.7%	118,526	178,792	110,081	192,635	186,353	179,456	149,340	137,624	119,575	27,734	20,021	25,859	24,417	35,897	75,210	119,455	33,065	29,198	64,877	91,200	60,911
Income Taxes	-54.2%	11,442	24,956	6,938	6,937	6,938	48,150	6,900	6,900	6,900	12,516	7,458	7,459	7,458	10,479	3,728	7,455	34,240	-6,812	4,462	4,462	-81,428
Earnings Before Taxes	69.9%	-1,891,030	-6,277,031	-1,056,281	869,091	179,224	-2,411,564	-416,326	-1,357,766	-1,395,533	-4,375,060	-1,576,022	732,143	-343,291	-1,777,051	-1,271,892	-1,671,756	-1,849,178	-3,376,139	-3,311,824	-1,334,059	-1,268,982
EBT Margin	-35.4%	-0.22	-0.16	-0.06	-0.04	-0.10	-0.13	-0.18	-0.23	-0.18	-0.15	-0.08	-0.07	-	-	-	-	-	-	-	-	-
Net Income	69.1%	-1,946,263	-6,294,406	-1,049,298	872,200	192,184	-2,440,729	-408,639	-1,335,620	-1,385,253	-3,847,697	-1,055,278	1,228,560	166,828	-883,776	-481,737	-918,275	-1,055,620	-960,706	-1,953,668	-549,507	-73,878
Net Income Margin	-36.6%	-0.22	-0.16	-0.06	-0.04	-0.10	-0.13	-0.17	-0.20	-0.14	-0.10	-0.01	0.00	-	-	-	-	-	-	-	-	-
Free Cashflow	-319.7%	-2,178,268	991,448	1,183,406	5,163,168	-1,525,469	3,791,559	2,543,892	2,193,281	-177,484	1,950,633	-161,961	2,684,148	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.3%	82.00	82.00	88.00	89.00	89.00	93.00	91.00	93.00	97.00	84.00	88.00	89.00	93.00	96.00	96.00	98.00	97.00	105	104	108	115
Current Assets	1.4%	36.00	36.00	42.00	44.00	44.00	46.00	49.00	44.00	45.00	46.00	47.00	47.00	49.00	50.00	49.00	46.00	45.00	50.00	49.00	52.00	58.00
Cash Equivalents	1.2%	19.00	18.00	19.00	18.00	16.00	20.00	20.00	18.00	17.00	27.00	26.00	26.00	25.00	25.00	27.00	27.00	27.00	28.00	27.00	21.00	25.00
Inventory	-6.1%	4.00	5.00	9.00	11.00	10.00	10.00	11.00	9.00	10.00	8.00	10.00	10.00	10.00	11.00	10.00	8.00	8.00	9.00	10.00	11.00	11.00
Net PPE	0.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	3.4%	54.00	53.00	52.00	53.00	53.00	57.00	52.00	53.00	56.00	42.00	41.00	41.00	46.00	50.00	48.00	49.00	48.00	53.00	52.00	54.00	59.00
Current Liabilities	-5.6%	26.00	28.00	27.00	27.00	26.00	29.00	25.00	24.00	25.00	19.00	18.00	19.00	23.00	26.00	24.00	23.00	19.00	24.00	21.00	22.00	28.00
Shareholder's Equity	-8.2%	27.00	30.00	36.00	37.00	36.00	36.00	39.00	39.00	41.00	43.00	47.00	48.00	47.00	47.00	48.00	48.00	50.00	51.00	52.00	54.00	55.00
Retained Earnings	-11.1%	-19.43	-17.49	-11.19	-10.14	-11.02	-11.21	-8.77	-8.36	-7.02	-5.64	-1.79	-0.74	-1.96	-2.13	-1.25	-0.77	0.00	1.00	2.00	4.00	5.00
Shares Outstanding	0.3%	14.00	14.00	14.00	14.00	14.00	14.00	15.00	15.00	15.00	15.00	15.00	15.00	-	-	-	-	-	-	-	-	-
Minority Interest	12.7%	-0.30	-0.34	-0.34	-0.32	-0.31	-0.29	-0.27	-0.26	-0.23	-0.21	-0.18	-0.14	-0.14	-0.12	-0.09	-0.07	-0.05	-0.04	-0.03	-0.37	-0.24
Float	-	-	-	-	12.00	-	-	-	17.00	-	-	-	24.00	-	-	-	31.00	-	-	-	57.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-305.4%	-2,136	1,040	1,237	5,235	-1,418	3,638	2,635	2,331	-150	1,960	-102	2,699	1,786	854	857	2,816	889	857	734	1,851	-385
Share Based Compensation	-16.1%	79.00	94.00	83.00	98.00	90.00	127	188	-27.75	160	225	162	192	163	241	262	278	265	378	347	397	364
Cashflow From Investing	-122.3%	-58.19	261	-95.07	-96.81	-174	-640	681	-172	-13,541	-26.79	-108	-48.51	-318	-316	-668	-201	-571	1,903	6,942	-4,823	-1,723
Cashflow From Financing	262.8%	2,422	-1,487	-882	-3,275	-1,779	-2,780	-1,991	-1,208	3,918	-735	383	-1,903	-1,298	-2,430	-915	-2,266	-1,503	-1,525	-1,649	-685	-1,220
Buy Backs	33.8%	247	184	201	172	188	201	79.00	197	566	361	238	485	303	304	333	770	442	899	1,362	532	704

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CPIX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenues	$ 8,497,701	$ 9,224,638
Costs and expenses:
Cost of products sold	1,575,542	1,250,264
Selling and marketing	4,154,588	4,277,318
Research and development	1,158,253	1,499,670
General and administrative	2,367,907	2,498,993
Amortization	1,110,661	1,230,071
Total costs and expenses	10,366,951	10,756,316
Operating loss	(1,869,250)	(1,531,678)
Interest income	96,746	50,190
Other income	0	1,847,065
Interest expense	(118,526)	(186,353)
Income (loss) before income taxes	(1,891,030)	179,224
Income tax expense	(11,442)	(6,938)
Net income (loss)	(1,902,472)	172,286
Net (income) loss at subsidiary attributable to noncontrolling interests	(43,791)	19,898
Net income (loss) attributable to common shareholders	$ (1,946,263)	$ 192,184
Earnings (loss) per share attributable to common shareholders
Basic (in USD per share)	$ (0.14)	$ 0.01
Diluted (in USD per share)	$ (0.14)	$ 0.01
Weighted-average shares outstanding
Basic (in shares)	14,098,022	14,359,322
Diluted (in shares)	14,098,022	14,587,843

CPIX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 18,548,485	$ 18,321,624
Accounts receivable, net	10,647,267	9,758,176
Inventories, net	4,327,526	4,609,362
Prepaid and other current assets	2,682,673	3,025,248
Total current assets	36,205,951	35,714,410
Non-current inventories	12,915,896	12,804,529
Property and equipment, net	369,499	367,903
Intangible assets, net	21,522,441	22,607,918
Goodwill	914,000	914,000
Operating lease right-of-use assets	6,521,088	6,674,394
Other assets	3,060,643	2,692,921
Total assets	81,509,518	81,776,075
Current liabilities:
Accounts payable	13,075,764	14,037,629
Operating lease current liabilities	362,244	348,092
Other current liabilities	12,987,372	13,596,528
Total current liabilities	26,425,380	27,982,249
Revolving line of credit	16,084,144	12,784,144
Operating lease non-current liabilities	5,200,148	5,296,247
Other long-term liabilities	6,610,294	6,453,566
Total liabilities	54,319,966	52,516,206
Shareholders’ equity:
Common stock—no par value; 100,000,000 shares authorized; 14,159,954 and 14,121,833 shares issued and outstanding as of March 31, 2024 and December 31, 2023 , respectively	46,923,757	47,091,602
Accumulated deficit	(19,434,424)	(17,488,161)
Total shareholders’ equity	27,489,333	29,603,441
Noncontrolling interests	(299,781)	(343,572)
Total equity	27,189,552	29,259,869
Total liabilities and equity	$ 81,509,518	$ 81,776,075

About Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

CEO	Mr. A. J. Kazimi MBA
WEBSITE	cumberlandpharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	85

Cumberland Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Cumberland Pharmaceuticals Inc? What does CPIX stand for in stocks?

CPIX is the stock ticker symbol of Cumberland Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cumberland Pharmaceuticals Inc (CPIX)?

As of Fri May 17 2024, market cap of Cumberland Pharmaceuticals Inc is 21.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CPIX stock?

You can check CPIX's fair value in chart for subscribers.

What is the fair value of CPIX stock?

You can check CPIX's fair value in chart for subscribers. The fair value of Cumberland Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cumberland Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CPIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cumberland Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CPIX is over valued or under valued. Whether Cumberland Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Cumberland Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CPIX.

What is Cumberland Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CPIX's PE ratio (Price to Earnings) is -2.55 and Price to Sales (PS) ratio is 0.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CPIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cumberland Pharmaceuticals Inc's stock?

In the past 10 years, Cumberland Pharmaceuticals Inc has provided -0.103 (multiply by 100 for percentage) rate of return.